Royalty Pharma (RPRX) Other Operating Expenses (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Other Operating Expenses data on file, last reported at -$131.8 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 3.63% year-over-year to -$131.8 million; the trailing twelve-month figure through Mar 2026 stood at -$160.9 million (down 840.84% YoY), and the FY2025 full-year result was -$206.8 million, down 128.23% from the prior year.
• Other Operating Expenses retreated to -$131.8 million in Q1 2026, from $18.8 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $924.7 million in Q4 2022 to a low of -$227.6 million in Q3 2024.
• A 5-year average of $148.9 million and a median of $118.8 million in 2023 frame the typical range for Other Operating Expenses.
• Peak annual rise in Other Operating Expenses reached 391.23% in 2024, while the deepest fall reached 182.13% in 2024.
• Tracing RPRX's Other Operating Expenses over 5 years: stood at $924.7 million in 2022, then sank by 108.27% to -$76.5 million in 2023, then soared by 314.39% to $164.0 million in 2024, then sank by 88.52% to $18.8 million in 2025, then tumbled by 799.47% to -$131.8 million in 2026.
• Business Quant data shows RPRX's Other Operating Expenses at -$131.8 million in Q1 2026, $18.8 million in Q4 2025, and $12.9 million in Q3 2025.